Understanding the global prevalence of APOE3 and APOE4 genotypes is crucial for Alzheimer’s disease (AD) research, particularly given the association between APOE4 and late-onset AD. The amyloid hypothesis, which links amyloid beta (Aβ) accumulation to AD progression, has heightened the importance of this research. Understanding APOE4 prevalence informs country and site selection for Phase III/IV AD trials, enabling targeted interventions in regions with high concentrations of undiagnosed, genetically vulnerable individuals.
Check out our infographic to learn about the global distribution of APOE3 and APOE4 and their implications for international site selection.
